Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Nektar Therapeutics    NKTR

Delayed Quote. Delayed  - 09/28 10:00:00 pm
17.67 USD   +1.84%
09/27 NEKTAR THERAPEU : to Host Investor & Analyst Conference Call to Disc..
08/03 NEKTAR THERAPEU : reports 2Q loss
08/03 NEKTAR THERAPEU : Reports Financial Results for the Second Quarter o..
News SummaryMost relevantAll newsSector news 
The feature you requested does not exist. However, we suggest the following feature:

NEKTAR THERAPEUTICS : Entry into a Material Definitive Agreement, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (form 8-K)

share with twitter share with LinkedIn share with facebook
share via e-mail
09/27/2016 | 01:50pm CEST

Item 1.01 Entry into a Material Definitive Agreement.

On September 21, 2016, Nektar Therapeutics, a Delaware corporation ("Nektar"), entered into a Clinical Trial Collaboration Agreement (the "Agreement") with Bristol-Myers Squibb Company, a Delaware corporation ("BMS"), pursuant to which Nektar and BMS will collaborate to conduct Phase 1/2 clinical trials evaluating Nektar's IL-2-based CD122-biased agonist, known as NKTR-214, and BMS's human monoclonal antibody that binds PD-1, known as Nivolumab, as a potential combination treatment regimen in five tumor types and seven potential indications, and such other clinical trials evaluating the combined therapy as may be mutually agreed upon by the parties (each, a "Combined Therapy Trial").

Under the Agreement, BMS will be responsible for 50% of all out-of-pocket costs reasonably incurred in connection with third party contract research organizations, laboratories, clinical sites and institutional review boards. Each party will otherwise be responsible for its own internal costs, including internal personnel costs, incurred in connection with each Combined Therapy Trial. Nektar and BMS will use commercially reasonable efforts to manufacture and supply its compound for each Combined Therapy Trial and will bear the costs related thereto. The parties will form a joint development committee to oversee clinical trial design, regulatory strategy, and other activities necessary to conduct and support the Combined Therapy Trials. Nektar will act as sponsor of each Combined Therapy Trial.

Ownership of, and global commercial rights to, NKTR-214 remain solely with Nektar under the Agreement. If Nektar wishes to license the right to commercialize NKTR-214 in one of certain major market territories prior to September 30, 2018 (the "Exclusivity Expiration Date"), Nektar must first negotiate with BMS, for a period of three months (the "Negotiation Period"), to grant an exclusive license to develop and commercialize NKTR-214 in any of these major market territories. If BMS and Nektar do not reach an agreement for an exclusive license within the Negotiation Period, Nektar will be free to license any right to NKTR-214 to other parties in any territory worldwide except that in the event that Nektar receives a license offer from a third party during a period of 90 calendar days after the end of the Negotiation Period, Nektar will provide BMS ten business days to match the terms of such third-party offer. After the Exclusivity Expiration Date, Nektar is free to license NKTR-214 without any further obligation to BMS.

Each party grants to the other party a non-exclusive, worldwide (subject to certain exceptions in the case of the license granted by BMS), non-transferable and royalty-free research and development license to such licensing party's patent rights, technology and regulatory documentation to use its compound solely to the extent necessary to discharge its obligations under the Agreement with respect to the conduct of the Combined Therapy Trials.

The Agreement also contains certain reciprocal exclusivity provisions that run until the Exclusivity Expiration Date. Nektar agrees not to conduct any preclinical or clinical research with, or grant rights under its proprietary intellectual property or relevant investigational new drug applications to, certain restricted third parties regarding an anti-PD-1 antagonist or anti-PD-L1 antagonist together with the NKTR-214 (a "Restricted NKTR-214 Combination"), and BMS agrees not to conduct any preclinical or clinical research with certain restricted third parties regarding Nivolumab together with an IL2-based CD122 agonist (a "Restricted Nivolumab Combination"). Nektar and BMS remain free to conduct any preclinical or clinical research-involving a Restricted NKTR-214 Combination in the case of Nektar and a Restricted Nivolumab Combination in the case of BMS-on their own or in collaboration with academic or other non-profit entities.

Subject to termination rights for breach, bankruptcy or a material safety issue/clinical hold, the term of the Agreement will continue in effect until completion by all centers or institutions participating in the Combined Therapy Trials, the delivery of study data to both parties and the completion of any then agreed upon protocol, statistical analysis and bioanalysis plan. In the event a third party merges with or acquires Nektar, Nektar is free to assign or transfer the Agreement without the consent of BMS.

The foregoing summary does not purport to be complete and is qualified in its entirety by reference to the Agreement, a copy of which will be filed as an exhibit to Nektar's Quarterly Report on Form 10-Q for the period ended September 30, 2016.

Item 7.01 Regulation FD Disclosure.

On September 27, 2016, BMS and Nektar jointly issued a press release attached hereto as Exhibit 99.1 ("Press Release"), announcing the entry into the Agreement.

The information in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, nor shall such information be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise stated in such filing.

 Item 8.01 Other Events.

On September 27, 2016, Nektar announced that it would hold a Webcast conference call on September 27, 2016, at 9:00 a.m. Eastern Time to review the collaboration with BMS and give an update on the NKTR-214 development program. This conference call is accessible through a link that is posted on the home page and Investor Relations section of the Nektar website: http://www.nektar.com. On this conference call, management expects to make certain forward-looking statements regarding the therapeutic potential of NKTR-214 both as a single agent and in combination with other cancer therapies such as Nivolumab, the potential benefits of the BMS collaboration, plans and expectations for the conduct and completion of future clinical studies, and certain other forward looking statements regarding Nektar's business. These forward-looking statements involve substantial risks and uncertainties including but not limited to:

· NKTR-214 is in early-stage clinical development and there are substantial risks that can unexpectedly occur for numerous reasons, including negative safety and efficacy findings in the ongoing Phase 1/2 clinical study notwithstanding positive findings from interim clinical results and preclinical studies;

· The clinical observations from the ongoing Phase 1/2 clinical trial of NKTR-214 are based on preliminary data from an ongoing clinical trial that is still actively enrolling patients and these preliminary data may not be representative of final results after all patients complete the trial and all data are collected and analyzed. Further, this preliminary data is subject to continuing audit and verification procedures that will not be complete until the conclusion of the trial and therefore the interim data is subject to change;

· The timing of the commencement or end of clinical trials and the availability of clinical data may be delayed or unsuccessful due to regulatory delays, slower than anticipated patient enrollment, manufacturing challenges, changing standards of care, evolving regulatory requirements, clinical trial design, clinical outcomes, competitive factors, or delay or failure in ultimately obtaining regulatory approval in one or more important markets;

· Scientific discovery of new medical breakthroughs is an inherently uncertain process and the future success of applying our technology platform to potential new drug candidates (such as NKTR-214) is therefore highly uncertain and unpredictable and one or more research and development programs could fail;

· Patents may not issue from our patent applications for our drug candidates including NKTR-214, patents that have issued may not be enforceable, or additional intellectual property licenses from third parties may be required; and

· Other important risks and uncertainties set forth in Nektar's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 4, 2016 and available at www.sec.gov.

Actual results could differ materially from the forward-looking statements made by management during the conference call and in the Press Release. Nektar undertakes no obligation to update forward-looking statements, whether as a result of new information, future events or otherwise.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Number    Description
99.1      Press Release titled "Bristol-Myers Squibb and Nektar Therapeutics Form
          Oncology Clinical Collaboration to Evaluate the Combination of Opdivo
          (nivolumab) and NKTR-214" issued on September 27, 2016.

© Edgar Online, source Glimpses

share with twitter share with LinkedIn share with facebook
share via e-mail
09/27 NEKTAR THERAPEUTICS : Entry into a Material Definitive Agreement, Regulation FD ..
09/27 NEKTAR THERAPEUTICS : to Host Investor & Analyst Conference Call to Discuss New ..
09/15 NEKTAR THERAPEUTICS : Researchers Submit Patent Application, "Self-Sealing T-Pie..
08/11 Nektar Therapeutics Reports Financial Results for the Second Quarter of 2016
08/04 NEKTAR THERAPEUTICS : Management's Discussion and Analysis of Financial Conditio..
08/03 NEKTAR THERAPEUTICS : Results of Operations and Financial Condition, Financial S..
08/03 NEKTAR THERAPEUTICS : reports 2Q loss
08/03 NEKTAR THERAPEUTICS : Reports Financial Results for the Second Quarter of 2016
07/27 NEKTAR THERAPEUTICS : to Announce Financial Results for the Second Quarter 2016 ..
06/27 NEKTAR THERAPEUTICS : Submission of Matters to a Vote of Security Holders (form ..
More news
Sector news : Biotechnology & Medical Research - NEC
09/27DJAMGEN : Myeloma Treatment Study Fails to Meet Primary Endpoint
09/26DJPfizer Throws Out Plan to Split Into Two Companies
09/26DJSANOFI : FDA Accepts Sanofi's, Regeneron's Dermatitis Treatment for Priority Rev..
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- Update
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
09/27 Bristol-Myers and Nektar Therapeutics to explore potential of Opdivo and NKTR..
09/15 BIOTECHNOLOGY : No Easy Way Out But Almost There!
09/13 Staying The Course! Stocks Remain Attractive
09/09 BIOTECH FORUM DAILY DIGEST : Biotech Tries To End Week On High Note. Lexicon Soa..
Financials ($)
Sales 2016 169 M
EBIT 2016 -113 M
Net income 2016 -147 M
Debt 2016 -
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales 2016 14,0x
Capi. / Sales 2017 11,5x
Capitalization 2 372 M
More Financials
Duration : Period :
Nektar Therapeutics Technical Analysis Chart | NKTR | US6402681083 | 4-Traders
Full-screen chart
Technical analysis trends NEKTAR THERAPEUTICS
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus BUY
Number of Analysts 8
Average target price 19,3 $
Spread / Average Target 11%
Consensus details
EPS Revisions
More Estimates Revisions
Howard W. Robin President, Chief Executive Officer & Director
Robert B. Chess Chairman
John Nicholson Chief Operating Officer & Senior Vice President
Gilbert M. Labrucherie Chief Financial Officer & Senior Vice President
Stephen K. Doberstein Chief Scientific Officer & Senior Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CELLTRION, INC.--.--%11 639
LONZA GROUP AG11.83%9 948
More Results